Impact of very low carbohydrate ketogenic diets on cardiovascular risk factors among patients with type 2 diabetes; GRADE-assessed systematic review and meta-analysis of clinical trials

Ghasemi P 1 , Jafari M 2 , Maskouni SJ 3 , Hosseini SA 4 , Amiri R 5 , Hejazi J 6 Show all authors , Chambari M 7 , Tavasolian R 6 , Rahimlou M 8

Affiliations 

  • 1 Research Committee, Medical School, Arak University of Medical Sciences, Arak, Iran
  • 2 Department of Exercise physiology, Faculty of Physical Education and Sports Sciences, Allameh Tabataba'i University, Tehran, Iran
  • 3 Department of nutrition, School of Public health, Jiroft University of Medical Sciences, Jiroft, Iran
  • 4 Department of Nutrition, School of Allied Medical Sciences, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  • 5 Mofid Childrens Hospital Clinical Research Development Unit, Shahid Beheshti University of Medical Science, Tehran, Iran
  • 6 Department of Nutrition, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran
  • 7 Department of Food Science and Nutrition, Faculty of Applied Sciences, UCSI University, 56000 Cheras, Wilayah Persekutuan Kuala Lumpur, Malaysia
  • 8 Department of Nutrition, School of Public Health, Zanjan University of Medical Sciences, Zanjan, Iran. Rahimlum@gmail.com
Nutr Metab (Lond), 2024 Jul 19;21(1):50.
PMID: 39030553 DOI: 10.1186/s12986-024-00824-w

Abstract

OBJECTIVE: This study was designed to evaluate the impact of VLCKD on cardiovascular risk factors in patients with T2DM.

METHODS: Until March 2024, extensive searches were conducted on PubMed, Scopus, Web of Science, Embase, and other relevant databases. The purpose was to identify clinical trials examining the impact of VLCKD on glycemic control, lipid profile, and blood pressure. The GRADE (Grading of Recommendations Assessment, Development, and Evaluation) method was used to assess the evidence's degree of certainty.

RESULTS: Our initial search found a total of 2568 records and finally 29 trials were included in final analysis. Our results showed that adherence from VLCKD led to significant reduction in fasting blood sugar (WMD= -11.68 mg/dl; 95% CI: -18.79, -4.56; P = 0.001), HbA1c (WMD= -0.29; 95% CI: -0.44, -0.14; P 

* Title and MeSH Headings from MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Similar publications